Colchiceine
- Research compound
- Still being tested
- Identity checked
- Sources last checked 2026-09-04
This page shows what was measured, who it was measured in, and what that does not settle.
What Colchiceine does in the body
Prophylaxis and the treatment of acute gout flares
From the FDA-approved label: The mechanism by which colchicine exerts its beneficial effect in patients with FMF has not been fully elucidated; however, evidence suggests that colchicine may interfere with the intracellular assembly of the inflammasome complex present in neutrophils and monocytes that mediates activation of interleukin-1β. Additionally, colchicine disrupts cytoskeletal functions through inhibition of β-tubulin polymerization into microtubules and consequently prevents the activation, degranulation and migration of neutrophils thought to mediate some gout symptoms.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
- Where it acts
- Not recorded.
- Kind of result
- No result is published, so no kind of result applies yet
- Supervision
- Professional supervision is normally required. It is a prescription or clinician-administered medicine where it is approved.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · HJ30158L57 · read 2026-08-29
Its recorded molecular formula is C22H25NO6, weighing 399.4.
US prescribing information · c8fd7034-5ca2-4a58-b303-7f78ffdf8d76 · read 2026-08-30
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 96 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Enzyme
An enzyme is a protein that speeds up one chemical change.
A picture of it, and where the picture fails
An enzyme is like a machine on a production line doing one cut.
Where that stops being true. A machine is switched on and off by a person. Enzymes are controlled by the cell.
What people get wrong. Enzymes are thought to be used up. They are not; they work again and again.
A catalytic protein that lowers the activation energy of a specific reaction.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in peopleRead from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 40 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
| Goal | Life outcome | What a body can do | How a person feels | A test result | A step in the body | Harms | How long | Who was studied |
|---|---|---|---|---|---|---|---|---|
| Pain | Nothing in the sources checkedNo registered study lists a life outcome for this goal. | Waiting for a reviewer1 registered performance measure of this kind. | Waiting for a reviewer3 registered symptom measure. | Nothing in the sources checkedNo registered study lists a test result for this goal. | Nothing in the sources checkedNo registered study lists a body-step measure for this goal. | Not recordedHarms were not a registered measure for this goal. | Not recordedNo finished study window is recorded. | Waiting for a reviewerWho was studied is listed further down the page. |
Which registered measures put each goal on this table
- Pain
- vas for shoulder pain; shoulder pain and disability index; pain intensity; intensity of pain
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
- Nothing in the sources checked
- No registered study lists a life outcome for this goal.
- Waiting for a reviewer
- 1 registered performance measure of this kind.
- Not recorded
- Harms were not a registered measure for this goal.
What happened in peopleRead from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
- Living longer, or avoiding a major event Evidence recorded. Death, a heart attack, a stroke, a hospital stay.1 registered measure of this kind. No reviewed result.
- What a body can do day to day Evidence recorded. Walking, dressing, breathing, recovering.1 registered measure of this kind.
- Measured performance Evidence recorded. How much was lifted, how far was run, how fast.1 registered measure of this kind.
- Symptoms and quality of life Evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.3 registered measures of this kind.
- A number that stands in for health Evidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.9 registered measures of this kind.
- A step measured inside a person Evidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
- Animals Evidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Drosophila (fruit fly), Mouse, Rat. A result in animals says what to test next. It does not say what happens in people.
- Cells in a dish Evidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
- A guess from software No evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to takeRead from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
- vas for shoulder pain
- pain intensity
- intensity of pain
Measured
Things only a test, a scale or a device shows.
- maximum plasma concentration
- 24 hr urine protein collection
- maximum serum concentration
- maximal plasma concentration
- time to maximum plasma concentration
- serum uric acid
- maximum plasma concentration of theophylline
- serum urate 5 0 / at month 3
- urinary protein excretion from baseline to 18 months
Meaningful
Things that change how a life goes, not only a number.
- shoulder pain and disability index
- overall survival
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (26)
- recurrence rate at 18 months
- postpericardiotomy syndrome
- proliferative vitreoretinopathy
- retinal reattachment rate
- iranian behcet s disease dynamic activity measurement
- frequency of ulcers
- core study mean number of gout flares per
- shoulder range of motion
- apparent first order terminal elimination rate constant
- apparent first order terminal elimination half life
- apparent total volume of distribution after administration
- gout flares per from day 1 to week 16
- psa response rate
- apparent total body clearance of theophylline
- apparent total volume of distribution of theophylline
- clinically significant atrial fibrillation
- acute gout flare times
- reduction in apociii levels
- improvement of rh pat at 1 month
- myocardial damage marker levels
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What it would be like to takeRead from sources, not yet reviewed
How long anything takes
Nine different lengths of time that get confused with each other. None of them is worked out from another.
Before anything is noticed. RNAWiki does not store this separately, and never works it out from another figure on this page.
Before a test result moves. RNAWiki does not store this separately, and never works it out from another figure on this page.
Before performance moves. RNAWiki does not store this separately, and never works it out from another figure on this page.
How long the result was watched. No finished study window is recorded for a study that tested this substance.
How long people took it. How long people actually took it is not stored. The study window is not the same thing.
How long people were followed. Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.
How fast the body clears it. 18.8 hours hours
Read from the label, which states: “Patients with end-stage renal disease had 75% lower colchicine clearance (0.17 vs. 0.73 L/hr/kg) and prolonged plasma elimination half-life (18.8 hours vs. 4.4 hours) as compared to subjects with FMF and normal renal function [see Dosage and Administration ( 2.5 ), Use in Specific Populations ( 8.6 )] .”
How long effects linger. RNAWiki does not store this separately, and never works it out from another figure on this page.
Beyond the studies. Nothing is recorded about the long term.
The longest finished study sets the edge of what anyone measured.
A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.
What is missing or unclearRead from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
- Colchicine tablets are an alkaloid indicated for: Prophylaxis and treatment of gout flares in adults ( 1.1 ). Familial Mediterranean fever (FMF) in adults and children 4 years or older ( 1.2 ). 1.1 Gout Flares Colchicine tablets are indicated for prophylaxis and the treatment of acute gout flares. Prophylaxis of Gout Flares: Colchicine tablets are indicated for prophylaxis of gout flares.
Who is missing from the studies
- Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The safety and efficacy of colchicine in children of all ages with FMF has been evaluated in uncontrolled studies.”
US prescribing information · c8fd7034-5ca2-4a58-b303-7f78ffdf8d76 · read 2026-08-30
On older people, the label states: “Clinical studies with colchicine for prophylaxis and treatment of gout flares and for treatment of FMF did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients.”
US prescribing information · c8fd7034-5ca2-4a58-b303-7f78ffdf8d76 · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Available data from published literature on colchicine use in pregnancy over several decades have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data).”
US prescribing information · c8fd7034-5ca2-4a58-b303-7f78ffdf8d76 · read 2026-08-30
On people who are breastfeeding, the label states: “8.3 Females and Males of Reproductive Potential Infertility Case reports and epidemiology studies in human male subjects on colchicine therapy indicated that infertility from colchicine is rare and may be reversible.”
US prescribing information · c8fd7034-5ca2-4a58-b303-7f78ffdf8d76 · read 2026-08-30
On people with reduced liver function, the label states: “The clearance of colchicine may be significantly reduced and plasma half-life prolonged in patients with chronic hepatic impairment compared to healthy subjects [see Clinical Pharmacology ( 12.3 )] .”
US prescribing information · c8fd7034-5ca2-4a58-b303-7f78ffdf8d76 · read 2026-08-30
On people with reduced kidney function, the label states: “Colchicine is significantly excreted in urine in healthy subjects.”
US prescribing information · c8fd7034-5ca2-4a58-b303-7f78ffdf8d76 · read 2026-08-30
Where the result stopped carrying
- This is a scope explorer, not a diagnosis engine.
- It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to takeRead from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
- A different form was studied
- The studied form is not the form on the shelf. Nothing in this record points to this reason.
- There was nothing to correct
- Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
- Something else had to happen too
- In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
- The change is too small to feel
- A real change can still sit below what a person notices. Nothing in this record points to this reason.
- Day-to-day swing hides it
- Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
- Not enough time yet
- The studies ran longer than the person has waited. Nothing in this record points to this reason.
- It was not taken as studied
- Missed days change the result, and studies count them. Nothing in this record points to this reason.
- Something else changed at the same time
- Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
- The product may not be what it says
- Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
- No recorded reason
- RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to takeRead from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Still being tested
Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral
Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. It is a prescription or clinician-administered medicine where it is approved.
Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
The identity record classes it as investigational; no register records an approval.
No source is stored against this line.
What is in the pack
Sold as tablet, given by the oral route.
Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to takeNothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclearRead from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral
Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
6 products list this as an active ingredient in the United States drug directory. 6 of them contain it and nothing else.
FDA National Drug Code directory · 70771-1590 · read 2026-08-29
They are sold as tablet, taken oral.
FDA National Drug Code directory · 70771-1590 · read 2026-08-29
4 published labels name it as an active ingredient. 4 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · c8fd7034-5ca2-4a58-b303-7f78ffdf8d76 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · c8fd7034-5ca2-4a58-b303-7f78ffdf8d76 · read 2026-08-29
Colchicine is oral at 3 DOSAGE FORMS AND STRENGTHS Colchicine tablets, USP 0.3 mg are purple, round, film-coated tablets, debossed with '1571' on one side and plain on other side., recorded as fda label in effect 2022-10-04 in the United States.
US prescribing information · c8fd7034-5ca2-4a58-b303-7f78ffdf8d76 · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to takeRead from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine, investigational agent. The questions below are for a clinician or pharmacist.
Questions worth asking
- Which of the trials of Colchiceine studied people like me?
- What was measured, and for how long?
- Was the result a laboratory value or a health outcome?
- What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclearRead from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Colchiceine are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in peopleRead from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Where else this substance is registered
- FDA substance identifier (UNII)
- HJ30158L57
- CAS registry number
- 477-27-0
- PubChem compound
- 234105
- RxNorm concept
- 2174385
- EMA substance identifier
- 300000053172
- European Chemicals Agency number
- 207-512-5
- DrugBank
- DB15534
Checks this page had to pass
Passed
Identity resolved
no open identity hold
Passed
No unresolved merge across substance families
no quarantine open
Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
Passed
Safety mode resolved
The identity record classes it as investigational; no register records an approval.
Passed
Canonical metadata present
slug and display name present
What is missing or unclearRead from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
The earliest marketing start date recorded for a listed product is 20190612.
FDA National Drug Code directory · 70771-1590 · read 2026-08-29
What is missing or unclearRead from sources, not yet reviewed
What to learn next
Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.
- Were people like me actually studied?
- How close is this evidence to something I would notice?
- What does nobody know about this yet?
- What is a stand-in result?
This order is fixed in code and does not count clicks or time on the page.
What is not here
6 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
- What happened in people — found nothing in the sources checked.
- The path through the body — found nothing in the sources checked.
- What it may clash with — found nothing in the sources checked.
- Other ways to the same goal — found nothing in the sources checked.
- Claims that go past the evidence — found nothing in the sources checked.
- What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (15)
What did Colchiceine's largest trial (70000 people) and its longest (19 years) measure?
70000 people in Colchiceine's largest registered study, 19 years in its longest registered window, measuring Overall mortality, new acute coronary syndrome, and ischemic stroke. ClinicalTrials.gov · 2026-09-01
73 phase2, 69 phase3, 50 phase4, 31 phase1, 19 na, 5 early phase1, 3 na or unstated; NCT04381936; 2038-09-30; no ageing endpoint recorded. Last human test completed 2026, NCT06203977.
Interpretation These counts include studies where Colchiceine was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
- phase273
- phase369
- phase450
- phase131
- na19
- early phase15
2 more recorded rows
- na or unstated3
- Last recorded human test NCT062039772026-04-04
recorded 2026-09-01 · last checked 2026-09-04
From Drosophila to human: where has Colchiceine shown lifespan?
Drosophila: mechanism-only, mouse: mechanism-only, rat: mechanism-only and human: lifespan (237): the rungs where Colchiceine has a recorded finding. Europe PMC and ClinicalTrials.gov · organism ladder · 2026-09-01
Interpretation Overall mortality, new acute coronary syndrome, and ischemic stroke. — the recorded outcome words.
Show the evidence
- Drosophilamechanism-only
- mousemechanism-only
- ratmechanism-only
- human NCT01906749lifespan; Overall mortality, new acute coronary syndrome, and ischemic stroke.; 237
recorded 2026-09-01 · last checked 2026-09-04
26 of Colchiceine's trials stopped: safety, accrual/recruitment, funding/business, other?
safety (1), accrual/recruitment (9), funding/business (2) and other (14): Colchiceine's stop wording, clustered. ClinicalTrials.gov · 2026-09-01
"Record is an ACRN grant summary \& not reflective of an individual trial. All ACTs conducted by ACRN were individually registered on the PRS."; 26 of 237 registered studies
Show the evidence
Trial
- NCT00000577withdrawn; "Record is an ACRN grant summary \& not reflective of an individual trial. All ACTs conducted by ACRN were individually registered on the PRS."
- NCT00840489terminated; "Preliminary analysis"
- NCT01481233withdrawn; "Due to funding"
- NCT02095522withdrawn; "The investigators did not find suiable patients"
- NCT02177266terminated; "Difficulty in recruiting patients"
- NCT02926248suspended; "Continuing IRB review was not submitted. Study was inactivated with the institutional IRB."
14 further recorded trials
- NCT02995512withdrawn; "feasibility"
- NCT03015831terminated; "Statistical analysis of interim data showed no advantage of colchicine"
- NCT03226899terminated; "This action was a business decision \& not related to any efficacy, safety or clinical concerns with lesinurad."
- NCT03575572terminated; "Staffing changes impacted by COVID-19 pandemic resulting in inadequate personnel to facilitate study."
- NCT03933007terminated; "faillure of recrutement"
- NCT04139655withdrawn; "Feasibility"
- NCT04218786withdrawn; "Due to the pandemic, there were logistical issues in continuing the study."
- NCT04322682terminated; "Due to several considerations (logistical, human and budgetary), the study was stopped early."
- NCT04326790terminated; "Slow enrollment as a result of the rapid flattening of the curve of COVID-19 cases in Greece"
- NCT04363437terminated; "Stopped due to widespread corticosteroid use in 2020 for COVID infection, which confounds and likely supercedes the effect of colchicine."
- NCT04367168terminated; "The intervention was not effective for the outcomes"
- NCT04375202terminated; "Insufficient rate of patient accrual and newly available scientific evidence"
- NCT04420624terminated; "Inclusion period completed"
- NCT04492358terminated; "No candidates for the recruitment"
recorded 2026-09-01 · last checked 2026-09-04
Human studies of Colchiceine used colchicine 0.6 mg tablet — over how long?
Human studies of Colchiceine used "colchicine 0.6 mg tablet". ClinicalTrials.gov · 2026-09-01
20 recorded entries; human; tablet; also "Colchicine 0.6 mg tablet", "Colchicine 0.6 mg", "Brand names: PMS Colchicine, Colchicine TAB 0.6 mg"
Show the evidence
human
- NCT01123395tablet; colchicine 0.6 mg tablet
- NCT01130051tablet; Colchicine 0.6 mg tablet
- NCT01985425Colchicine 0.6 mg
- NCT01985425Brand names: PMS Colchicine, Colchicine TAB 0.6 mg
- NCT01994226Colchicine 500 mcg
- NCT02995512Colchicine 0.6 mg tablets
14 more recorded rows
- human NCT03376698Colchicine 0.5 mg
- human NCT03376698Colchicine 0.25 mg
- human NCT03693781Colchicine 1 MG Oral Tablet
- human NCT04539873Colchicine 0.5 MG
- human NCT04774159Colchicine 0.5 MG Oral Tablet
- human NCT04875702Colchicine 1.2 mg
- human NCT05200052Colchicine 0.5 mg Oral Tablet
- human NCT06020300Oral Colchicine 0.6 mg
- human NCT06078904Colchicine 0.375 MG
- human NCT06078904Colchicine 0.25 MG
- human NCT06472908Colchicine 0.375 mg
- human NCT06930885Colchicine-placebo 0.5 mg
- human NCT06936709Colchicine 1.8 mg (loading dose) + Dextrose Oral Placebo
- human NCT06936709Colchicine 1.8 mg + 0.6 mg
recorded 2026-09-01 · last checked 2026-09-04
More Colchiceine was worse in human: at what point?
Hormetic in human: "Furthermore, an in vitro phytotoxicity assay of colchicine-treated cucumber radicles indicated a hormetic-type concentration-dependent response with macroscopic changes in radicles and hypocotyl." Europe PMC · dose-response search · 2026-04-24
5 recorded sentences naming Colchiceine; hormetic, dose-response
Show the evidence
- hormetic PMID 35890440"Furthermore, an in vitro phytotoxicity assay of colchicine-treated cucumber radicles indicated a hormetic-type concentration-dependent response with macroscopic changes in radicles and hypocotyl."
dose-response
- PMID 42029810"To our knowledge, this work provides the first systematic dose-response analysis for transdermal colchicine delivered via microneedles, offering a promising non-oral alternative and supporting further development of this strategy."
- PMID 41832698"Nonetheless, further studies are warranted to optimize drug delivery strategies, explore dose-response relationships, and compare colchicine with standard stent-based therapies."
- PMID 37894398"A notable finding was that the prolonged use of colchicine was associated with improved outcomes, indicating a potential dose-response relationship. <b>Conclusions:</b> This study proposes a potential new role for colchicine in liver cancer prevention, extending beyond its established anti-inflammatory applications."
- PMID 37324937"Notably, treatment of colchicine in LPS-stimulated mice resulted in a U-shape dose-response curve, where greatly improved survival rates were observed only at doses between 0.10-0.40 mg/kg. At this therapeutic dose level, colchicine inhibited the expression of all the identified hub genes and effectively rescued the pathogenic phenotypes observed in LPS-stimulated mice and iPSC-aCM models.…"
recorded 2026-04-24 · last checked 2026-09-04
Colchiceine's half-life is 18.8 hours — which schedules were studied?
18.8 hours, the half-life Colchiceine's label states. openfda-label · ac12e420-9f29-018e-e053-2a95a90ab612 · 2026-08-30
bioavailability 45% %.
Show the evidence
- half life18.8 hours hours; Patients with end-stage renal disease had 75% lower colchicine clearance (0.17 vs. 0.73 L/hr/kg) and prolonged plasma elimination half-life (18.8 hours vs. 4.4 hours) as compared to subjects with FMF and normal renal function [see Dosage and Administration ( 2.5 ), Use in Specific Populations ( 8.6 )] .
- tmaxMean (%CV) Pharmacokinetic Parameters in Healthy Adults Given Colchicine C max (Colchicine ng/mL) T max* (h) Vd/F (L) CL/F (L/hr) t 1/2 (h) Colchicine 0.6 mg Single Dose (N=13) 2.5 (28.7) 1.5 (1 to 3) 341.5 (54.4) 54.1 (31) - Colchicine 0.6 mg Twice Daily x 10 Days (N=13) 3.6 (23.7) 1.3 (0.5 to 3) 1150 (18.7) 30.3 (19) 26.6 (16.3) * T max mean (range) CL = Dose/AUC 0-t (calculated from mean…
- bioavailability45% %; Absolute bioavailability is reported to be approximately 45%.
- metabolismMetabolism Colchicine is demethylated to two primary metabolites, 2-O-demethylcolchicine and 3-O-demethylcolchicine (2- and 3-DMC, respectively) and one minor metabolite, 10-O-demethylcolchicine (also known as colchiceine).
recorded 2026-08-30 · last checked 2026-09-04
Could one person measure Colchiceine's effect on recurrence rate at 18 months?
Recurrence rate at 18 months: measured in Colchiceine's trials.
recurrence rate at 18 months is the recorded endpoint.
Show the evidence
biomarkers
- recurrence rate at 18 months; 2026-09-01
- postpericardiotomy syndrome; 2026-09-01
- proliferative vitreoretinopathy; 2026-09-01
- retinal reattachment rate; 2026-09-01
- iranian behcet s disease dynamic activity measurement; 2026-09-01
- frequency of ulcers; 2026-09-01
14 more recorded rows
- biomarkerscore study mean number of gout flares per; 2026-09-01
- biomarkersvas for shoulder pain; 2026-09-01
- biomarkersshoulder range of motion; 2026-09-01
- biomarkersshoulder pain and disability index; 2026-09-01
- biomarkersmaximum plasma concentration; 2026-09-01
- biomarkers24 hr urine protein collection; 2026-09-01
- biomarkersmaximum serum concentration; 2026-09-01
- biomarkersmaximal plasma concentration; 2026-09-01
- biomarkerstime to maximum plasma concentration; 2026-09-01
- biomarkersapparent first order terminal elimination rate constant; 2026-09-01
- biomarkersapparent first order terminal elimination half life; 2026-09-01
- biomarkersapparent total volume of distribution after administration; 2026-09-01
- biomarkersserum uric acid; 2026-09-01
- biomarkersgout flares per from day 1 to week 16; 2026-09-01
- half life2026-09-04; halfLife; hours; 18.8 hours; 2026-08-30
- human trials at or under3054
- smallest human trial0; NCT00000577; PHASE3; the smallest recorded human enrolment at or below 30; the registry states no direction of its result; WITHDRAWN
Which of 24 hr urine protein collection, acute gout flare times and apparent first order terminal elimination half life did Colchiceine's trials measure?
24 hr urine protein collection, acute gout flare times and apparent first order terminal elimination half life lead 40 outcome terms across Colchiceine's trials. ClinicalTrials.gov · 2026-09-01
Interpretation retinal reattachment rate, iranian behcet s disease dynamic activity measurement, frequency of ulcers, core study mean number of gout flares per, vas for shoulder pain and shoulder range of motion follow.
Show the evidence
- recurrence rate at 18 months1
- postpericardiotomy syndrome1
- proliferative vitreoretinopathy1
- retinal reattachment rate1
- iranian behcet s disease dynamic activity measurement1
- frequency of ulcers1
14 more recorded rows
- core study mean number of gout flares per1
- vas for shoulder pain1
- shoulder range of motion1
- shoulder pain and disability index1
- maximum plasma concentration1
- 24 hr urine protein collection1
- maximum serum concentration1
- maximal plasma concentration1
- time to maximum plasma concentration1
- apparent first order terminal elimination rate constant1
- apparent first order terminal elimination half life1
- apparent total volume of distribution after administration1
- serum uric acid1
- gout flares per from day 1 to week 161
recorded 2026-09-01 · last checked 2026-09-04
Which of Colchiceine's 58 ongoing trials reports first?
58 registered trials of Colchiceine are open; earliest completion 2025-02. ClinicalTrials.gov · 2026-09-01
Efficacy of the study drugs for the treatment of skin vasculitis.; Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling; latest 2038-09-30
Show the evidence
Trial
- NCT02939573"A Randomized Multicenter Study for Isolated Skin Vasculitis"; n 90; "Efficacy of the study drugs for the treatment of skin vasculitis."; 2028-12-31
- NCT04278404"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)"; n 5000; "Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling"; 2026-12
- NCT04381936"Randomised Evaluation of COVID-19 Therapy"; n 70000; "Community-acquired pneumonia: All-cause mortality (with subsidiary analyses of cause of death and of death at various timepoints following discharge)"; 2038-09-30
- NCT04500665"Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine"; n 20; "Between-group change in left ventricular global longitudinal strain"; 2026-11-11
- NCT04774159"Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk"; n 6150; "Major adverse cardiovascular and limb events (MACE or MALE)"; 2029-12
- NCT04875702"Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout"; n 650; "Frequency of gout flare"; 2028-10-31
14 further recorded trials
- NCT04916522"The COlchicine HypERtENsion Trial"; n 150; "Between-group difference in change in carotid-femoral pulse wave velocity at 6 months"; 2026-01
- NCT05162742"Colchicine and Inflammation in Aortic Stenosis"; n 150; "Change in aortic valve calcium score"; 2026-12
- NCT05175274"Colchicine Use for Primary Prevention of Coronary Artery Disease"; n 6792; "The incidence of CAD"; 2028-07-01
- NCT05472337"Effect of Colchicine on Coronary Reperfusion in Patients With Acute Coronary Syndrome"; n 50; "Change in Index of Microcirculatory resistance (IMR) between pre and post-coronary angioplasty."; 2026-06-30
- NCT05476991"Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis"; n 2800; "Number of Participants with nonfatal ischemic stroke"; 2027-09-01
- NCT05503225"Colchicine Use in Intracranial Atherosclerotic Disease"; n 72; "Regression of intracranial stenosis"; 2028-05-31
- NCT05618353"The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial"; n 700; "Major adverse cardiovascular events"; 2029-04-30
- NCT05633810"COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes"; n 10000; "First event of the composite of cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, or urgent hospitalization for angina requiring coronary revascularization."; 2027-12
- NCT05690204"Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001."; n 87; "primary"; 2025-02
- NCT05850091"Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine"; n 200; "Change in total non-calcified plaque volume from baseline to one year"; 2027-06-01
- NCT05855746"Colchicine Versus Placebo in Acute Myocarditis Patients"; n 300; "Extent of Late Gadolinium Enhancement (LGE) evaluated on Cardiac Magnetic Resonance (CMR)"; 2028-07-16
- NCT05873881"COLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease"; n 2500; "Colchicine arm: Time to first occurrence of a CV death, a HF event, MI, stroke, or arterial revascularization"; 2027-06
- NCT05890664"Colchicine After Electrocardioversion for Atrial Fibrillation"; n 416; "Number of atrial fibrillation (AF) recurrence"; 2027-03
- NCT05928728"The COLchicine and Atrial FIBrillation Trial"; n 500; "Between-group difference in change in time to first AF admission measured in days"; 2028-11-01
recorded 2026-09-01 · last checked 2026-09-04
Which running trial of Colchiceine could settle inflammatory markers?
NCT07287345 measures Change in Inflammatory markers, reading out 2026-12-30.
7 open trials; n 24; "Colchicine's Effect on Inflammatory Markers"
Show the evidence
Trial
- NCT07287345"Colchicine's Effect on Inflammatory Markers"; n 24; "Change in Inflammatory markers"; 2026-12-30
- NCT06768294"Baricitinib in CPPD - the BAPTIST Study"; n 32; "The evaluation the effect of baricitinib on inflammation of the synovial membrane in CPPD"; 2027-01
- NCT07571681"Colchicine for Autoimmune and Subacute Thyroiditis"; n 300; "Mean Change in C-Reactive Protein (CRP)"; 2027-09
- NCT06286423"Colchicine in Acutely Decompensated HFREF"; n 30; "Difference in the change in high sensitivity C-reactive protein (hsCRP) between colchicine arm and placebo arm in the first 72 hours of treatment"; 2028-06
- NCT07704164"Colchicine to Reduce Coronary Artery Inflammation in People With HIV"; n 90; "Changes in coronary artery inflammation"; 2029-06
- NCT05949281"Repurposing Colchicine for Reduction of Residual Inflammatory Risk in Type 1 Diabetes"; n 102; "Change in fasting serum/plasma concentrations of C-reactive protein (CRP) measured by a high-sensitivity assay (hsCRP) (mg/L)"; 2031-01-15
- 1 further recorded trial NCT04381936"Randomised Evaluation of COVID-19 Therapy"; n 70000; "Community-acquired pneumonia: All-cause mortality (with subsidiary analyses of cause of death and of death at various timepoints following discharge)"; 2038-09-30
Which 64 trials of Colchiceine posted no result?
- Posted no result
- 64 of 64 completed trials
- Registrations
- NCT00700297, NCT00754819, NCT00128427, NCT00128414, NCT01416402 and NCT01336686, and 58 more
- Completion dates
- oldest 2006-05; newest 2024-08-09
Show the evidence
Trial
- NCT007002972006-05
- NCT007548192009-09
- NCT001284272010-06
- NCT001284142010-10
- NCT014164022011-10
- NCT013366862011-11
14 further recorded trials
- NCT002350792011-12
- NCT011602762012-01
- NCT001284532012-06
- NCT026020282013-08
- NCT020605522014-04
- NCT020835102014-05
- NCT021224842014-11
- NCT022528352014-12
- NCT020639972015-01
- NCT021764602015-09
- NCT023307962015-11
- NCT021623032016-01
- NCT031315832018-01-29
- NCT036590582018-08-01
At the median, Colchiceine's trials enrolled 100 people — anything larger?
- Median enrolment
- 100
- Largest enrolment
- 70000
- Registered trials counted
- 236
Colchiceine and CYP3A4, CYP1A2 and CYP2A6: shared by which compounds?
CYP3A4, CYP1A2 and CYP2A6 appear in Colchiceine's recorded interaction sentences, 10 in all. openfda-label+europepmc · 2026-08-30
Interpretation pharmacokinetics
Show the evidence
- CYP1A2 pharmacokineticsDrug Interactions In Vitro Drug Interactions In vitro studies in human liver microsomes have shown that colchicine is not an inhibitor or inducer of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4 activity.
- CYP2A6 pharmacokineticsDrug Interactions In Vitro Drug Interactions In vitro studies in human liver microsomes have shown that colchicine is not an inhibitor or inducer of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4 activity.
- CYP2B6 pharmacokineticsDrug Interactions In Vitro Drug Interactions In vitro studies in human liver microsomes have shown that colchicine is not an inhibitor or inducer of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4 activity.
- CYP2C19 pharmacokineticsDrug Interactions In Vitro Drug Interactions In vitro studies in human liver microsomes have shown that colchicine is not an inhibitor or inducer of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4 activity.
- CYP2C8 pharmacokineticsDrug Interactions In Vitro Drug Interactions In vitro studies in human liver microsomes have shown that colchicine is not an inhibitor or inducer of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4 activity.
- CYP2C9 pharmacokineticsDrug Interactions In Vitro Drug Interactions In vitro studies in human liver microsomes have shown that colchicine is not an inhibitor or inducer of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4 activity.
2 more recorded rows
- CYP2D6 pharmacokineticsDrug Interactions In Vitro Drug Interactions In vitro studies in human liver microsomes have shown that colchicine is not an inhibitor or inducer of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4 activity.
- CYP2E1 pharmacokineticsDrug Interactions In Vitro Drug Interactions In vitro studies in human liver microsomes have shown that colchicine is not an inhibitor or inducer of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4 activity.
CYP3A4
- pharmacokineticsIn vitro studies using human liver microsomes have shown that CYP3A4 is involved in the metabolism of colchicine to 2-and 3-DMC.
- pharmacokineticsDrug Interactions In Vitro Drug Interactions In vitro studies in human liver microsomes have shown that colchicine is not an inhibitor or inducer of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4 activity.
recorded 2026-08-30 · last checked 2026-09-04
Was Colchiceine studied with fasting and exercise?
fasting and exercise are named in Colchiceine's label sentences: "However, changes in some secondary outcomes, including homeostatic model assessment of insulin resistance (P = 0.0499), fasting insulin (P = 0.07) and glucose effectiveness (P = 0.08), suggested metabolic improvements in the colchicine versus placebo group." openfda-label+europepmc · 2026-08-30
2 recorded statements; fasting, exercise
Show the evidence
- fastingHowever, changes in some secondary outcomes, including homeostatic model assessment of insulin resistance (P = 0.0499), fasting insulin (P = 0.07) and glucose effectiveness (P = 0.08), suggested metabolic improvements in the colchicine versus placebo group.
- exerciseAccording to this prospective, randomized study, anti-inflammatory treatment with colchicine in patients with stable CHF, although effective in reducing inflammation biomarker levels, did not affect in any significant way patient functional status (in terms of New York Heart Association class and objective treadmill exercise tolerance) or the likelihood of death or hospital stay for heart failure.
recorded 2026-08-30 · last checked 2026-09-04
What is recorded about Colchiceine and mTOR?
"Colchicine treatment significantly reduced systolic and diastolic pressure in the model group, improved cardiac function, modulated mTOR- and autophagy-related gene expression, and attenuated myocardial fibrosis and inflammatory factor release." — where Colchiceine and mTOR appear together. Europe PMC · pathway abstract search · 2026-07-27
mTOR, autophagy, AMPK, IGF-1, NAD+, sirtuin; PMID 42565417, 39107264, 42346279, 38018843
Show the evidence
- mTOR PMID 42565417"Colchicine treatment significantly reduced systolic and diastolic pressure in the model group, improved cardiac function, modulated mTOR- and autophagy-related gene expression, and attenuated myocardial fibrosis and inflammatory factor release."
- autophagy PMID 42565417"Colchicine treatment significantly reduced systolic and diastolic pressure in the model group, improved cardiac function, modulated mTOR- and autophagy-related gene expression, and attenuated myocardial fibrosis and inflammatory factor release."
- mTOR PMID 42565417"These results support colchicine as a promising therapeutic agent targeting the mTOR-autophagy axis in HFpEF."
- autophagy PMID 42565417"These results support colchicine as a promising therapeutic agent targeting the mTOR-autophagy axis in HFpEF."
- mTOR PMID 42565417"Colchicine may modulate mTOR signaling, regulate autophagy, reduce inflammation, and alleviate myocardial fibrosis in HFpEF."
- autophagy PMID 42565417"Colchicine may modulate mTOR signaling, regulate autophagy, reduce inflammation, and alleviate myocardial fibrosis in HFpEF."
6 more recorded rows
- AMPK PMID 39107264"Here, we identified a novel anti-HBc compound-colchicine, an alkaloid compound-that promoted selective autophagic degradation of HBc through the AMPK/mTOR/ULK1 signalling pathway."
- IGF-1 PMID 42346279"Fourteen studies, including 1144 children, were analyzed, evaluating height, growth velocity, IGF-1 levels, and treatment effects of colchicine or IL-1-targeted biologics. <i>Results:</i> Growth was generally preserved in a considerable number of children with FMF."
- NAD+"Following irradiation, colchicine restored ALDH2, reduced mitochondrial (mt)ROS - dependent p90 ribosomal S6 kinase ( p90RSK ) activation and lipid peroxidation, preserved TET2 and DNMT3A expression, and rescued impaired efferocytosis while preventing nicotinamide adenine dinucleotide (NAD⁺) and adenosine triphosphate (ATP) depletion."
- AMPK PMID 38018843"Targeting the enzyme may provide new therapeutic approaches for mitigating skeletal muscle atrophy.<b>Abbreviation</b>: ADMA: asymmetric dimethylarginine; AKT/protein kinase B: AKT serine/threonine kinase; AMPK: AMP-activated protein kinase; ATG: autophagy related; BECN1: beclin 1; BNIP3: BCL2 interacting protein 3; CARM1: coactivator associated arginine methyltransferase 1; Col: colchicine; CSA:…"
- sirtuin PMID 38018843"Targeting the enzyme may provide new therapeutic approaches for mitigating skeletal muscle atrophy.<b>Abbreviation</b>: ADMA: asymmetric dimethylarginine; AKT/protein kinase B: AKT serine/threonine kinase; AMPK: AMP-activated protein kinase; ATG: autophagy related; BECN1: beclin 1; BNIP3: BCL2 interacting protein 3; CARM1: coactivator associated arginine methyltransferase 1; Col: colchicine; CSA:…"
- AMPK PMID 38172692"Mechanistically, colchicine increased the phosphorylation level of adenosine monophosphate-activated protein kinase (AMPK), promoted the expression of silent information regulation T1 (SIRT1), and inhibited the expression of NOD-like receptor pyrin containing 3 (NLRP3) to reduce myocardial pyroptosis."
sirtuin
- PMID 38172692"Mechanistically, colchicine increased the phosphorylation level of adenosine monophosphate-activated protein kinase (AMPK), promoted the expression of silent information regulation T1 (SIRT1), and inhibited the expression of NOD-like receptor pyrin containing 3 (NLRP3) to reduce myocardial pyroptosis."
- PMID 38172692"Colchicine improves CME-induced cardiac dysfunction and myocardial injury by inhibiting cardiomyocyte pyroptosis through the AMPK/SIRT1/NLRP3 signaling pathway."
recorded 2026-07-27 · last checked 2026-09-04
Where it is registered
Identifiers, relations and other names
The exact record
- UNII
- HJ30158L57
- PubChem CID
- 234105
- CAS number
- 477-27-0
- RxCUI
- 2174385
- InChIKey
- PRGILOMAMBLWNG-HNNXBMFYSA-N
- Trade name
- Colchicine
- Also called
- COLCHICEINE [MI], COLCHICINE IMPURITY F [EP IMPURITY], O10-DEMETHYLCOLCHICINE
- Development code
- NSC-123396, NSC-33411
Sources (10)
Sources
- ClinicalTrials.gov clinicaltrials.gov ·
- ClinicalTrials.gov ClinicalTrials.gov API v2 snapshot 2026-09-01T09:00:05 ·
- this record's own fields 2,3,5 ·
- Europe PMC dose-response search ·
- Europe PMC pathway abstract search ·
- Europe PMC search ·
4 more sources
- Europe PMC and ClinicalTrials.gov organism ladder ·
- openfda-label ac12e420-9f29-018e-e053-2a95a90ab612 ·
- openfda-label+europepmc K1:HJ30158L57 ·
- national registers US, CA ·
ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
How these records are assembled · Which registers were checked
Index-quality checks
- identity passed: no open identity hold
- required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
- public claims reviewed: 0 reviewed claim(s); drafts are never rendered
- source coverage passed: 10 source rows
- no critical contamination: no quarantine open
- canonical metadata passed: slug and display name present
- no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.